References
- Tocut M, Rozman Z, Biro A, et al. Comparison of the Birmingham
Vasculitis Activity Score and the Five-Factor Score to assess survival
in antineutrophil cytoplasmic antibody-associated vasculitis: a study
of 550 patients from spain (REVAS Registry). Arthritis Care Res
(Hoboken). 2020;72(7):1001-1010..
- Rathmann J, Jayne D, Segelmark M, et al. Incidence and predictors of
severe infections in ANCA-associated vasculitis: a population-based
cohort study. Rheumatology (Oxford). 2020 Nov 30; keaa699.
- Sakai R, Tanaka E, Nishina H, et al. Risk of opportunistic infections
in patients with antineutrophil cytoplasmic antibody-associated
vasculitis, using a Japanese health insurance database. Int J Rheum
Dis . 2019;22(11):1978-1984.
- Konigsberg MW, Wu CH, Strauch RJ. Topical treatment for cutaneous
mucormycosis of the upper extremity. J Hand Surg Am.
2020;45(12):1189.e1-1189.e5.
- Zhan HX, Lv Y, Zhang Y, et al. Hepatic and renal artery rupture due to
Aspergillus and Mucor mixed infection
after combined liver
and kidney transplantation: a case report. Transplant Proc .
2008;40(5):1771-1773.
- Paul SR, Gable PS. Mucormycosis as the elusive cause of an aortic
thrombus and tissue-obliterating abscess. Case Rep Hematol.
2019:4842150.
- Godara SM, Kute VB, Goplani KR, et al.
Mucormycosis in renal
transplant recipients: predictors and outcome. Saudi J Kidney Dis
Transpl. 2011;22(4):751-756.
- Waki D, Nishimura K, Tokumasu H, et al. Initial high-dose
corticosteroids and renal impairment are risk factors for early severe
infections in elderly patients with antineutrophil cytoplasmic
autoantibody-associated vasculitis: A retrospective observational
study. Medicine (Baltimore). 2020;99(8):e19173.
- Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, et al. Prevalence
and risk factors for major infections in patients with antineutrophil
cytoplasmic antibody-associated vasculitis: influence on the disease
outcome. J Rheumatol. 2020;47(3):407-414.
- Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features
and outcomes. Infection. 2017;45(4):443-448.
- Lee SC, Li A, Calo S, et al. Calcineurin orchestrates dimorphic
transitions, antifungal drug responses and host-pathogen interactions
of the pathogenic mucoralean fungus Mucorcircinelloides. Mol
Microbiol. 2015;97(5):844-865.
- Inagaki N, Sugimoto K, Hosone M, et al. Disseminated Mucor infection
and thrombotic microangiopathy in lymphoma-associated hemophagocytic
syndrome. Int J Hematol. 2008;88(3):355-356.
- Santos Silva J, Torres C, Clemente S, et al. Isolated Pulmonary
Mucormycosis in an immunocompetent patient. Rev Port Cir Cardiotorac
Vasc. 2019;26(2):151-153.
- Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the
Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis.
2009;68(12):1827-1832.
- Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated
vasculitis_mechanisms and implications for management. Nat Rev
Nephrol. 2017;13(6):359-367.
- KaKallenberg CG, Heeringa P. Complement system activation in ANCA
vasculitis: A translational success story? Mol Immunol.
2015;68(1):53-56.
- García L, Pena CE, Maldonado RÁ, et al. Increased renal damage in
hypocomplementemic patients with ANCA-associated vasculitis:
retrospective cohort study. Clin Rheumatol. 2019;38(10):2819-2824.
Fig. 1 Chest CT scan of the patient on May 4, 2017.